 --Conference Call and Webcast today at 4:30pm ET--HAMPTON, N.J., Aug. 06, 2020 GLOBE NEWSWIRE -- Celldex Therapeutics, Inc. NASDAQ:CLDX today reported business and financial highlights for the second quarter ended June 30, 2020. The Company will host a conference call at 4:30 p.m. ET today to provide an update on its pipeline and upcoming milestones. In the second quarter of 2020, we presented data from our KIT inhibitor, CDX-0159, in a late breaking session at the EAACI Annual Congress that suggested significant potential to dramatically impact mast cell driven disorders, said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. These data provided important proof of concept for the CDX-0159 program and helped support a 150 million public offering driven by high quality health care investors to fully fund the Companys planned operations through 2023. We are on track to initiate two studies in chronic urticaria later this year and are vetting additional mast cell driven indications to support expanded development in 2021. We continue to focus our resources on the programs we believe hold the most promise for patients and shareholders and have prioritized the development of CDX-0159, CDX-1140, and the first candidate from our bi-specific program, CDX-527. We are discontinuing development of CDX-3379, which is in an exploratory study with cetuximab to assess the utility of biomarkers in head and neck cancer. The side effect profile of the combination remains challenging even with prophylactic treatment and, when considered with the emerging clinical activity, we believe our resources are best utilized to expand the development of CDX-0159 and our other pipeline programs. To this end, we intend to start the two planned studies of CDX-0159 this fall and to initiate a combination cohort of CDX-1140 with chemotherapy in treatment naïve metastatic pancreatic cancer and a Phase 1 study of CDX-527 in refractory, advanced cancers later this year. These programs will support data read outs later this year and in 2021, concluded Marucci.Recent Pipeline Highlights CDX-0159a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity. The KIT receptor tyrosine kinase is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. Results from the Phase 1a dose escalation study of CDX-0159 were featured in a late breaking presentation in June at the European Academy of Allergy and Clinical Immunology EAACI Annual Congress 2020. CDX-0159 demonstrated a favorable safety profile as well as profound and durable reductions of plasma tryptase, indicative of systemic mast cell ablation. Tryptase suppression below the level of detection was observed after a single 1.0 mgkg dose and was maintained for more than 2 months at single doses of both 3.0 and 9.0 mgkg of CDX-0159. -- As indicated in the EAACI presentation, a subset of subjects from the 3mgkg and 9 mgkg cohorts agreed to continued follow up for tryptase suppression. This follow up and analysis was completed in July and tryptase levels remained below the level of detection for over 3 months 14 weeks in 50 of subjects in the 3 mgkg cohort and over 4 months 18 weeks in all subjects in the 9 mgkg cohort. Celldex plans to initiate Phase 1b studies of CDX-0159 in chronic spontaneous urticaria CSU and chronic inducible urticaria CIndU, both mast cell driven diseases, this fall. Celldex is exploring cold-induced and symptomatic dermographism scratch-induced urticarias. Celldex is also exploring additional mast cell driven diseases for potential future development, including mast cell activation syndromes, asthma, allergic conditions and mast cell driven gastrointestinal disorders. Data from the Phase 1b studies in CIndU and CSU are anticipated in the first quarter and second half of 2021, respectively. CDX-1140a potent CD40 human agonist antibody developed by Celldex that the Company believes has the potential to successfully balance systemic doses for good tissue and tumor penetration with an acceptable safety profile. In the Phase 1 dose-escalation study of CDX-1140 in patients with recurrent, locally advanced or metastatic solid tumors and B cell lymphomas, both the monotherapy and combination with CDX-301 dose escalation portions of the trial are complete with an identified maximum tolerated dose MTD and recommended Phase 2 dose of CDX-1140 at 1.5 mgkgone of the highest systemic dose levels in the CD40 agonist class. Expansion cohorts are actively recruiting including: -- CDX-1140 with KEYTRUDA pembrolizumab in patients who have progressed on checkpoint therapy; and, -- CDX-1140 with CDX-301 in patients with head and neck squamous cell carcinoma HNSCC; and, -- A combination of CDX-1140 with standard of care chemotherapy in first line metastatic pancreatic cancer is expected to initiate later this year. A data update from the ongoing Phase 1 study is planned for presentation in the fall of 2020.CDX-527the first candidate developed by Celldex from its bispecific platform which utilizes the Companys proprietary highly active anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1PD-1 pathway. Celldex anticipates initiating a Phase 1 dose-escalation study in up to 90 patients with advanced or metastatic solid tumors that have progressed during or after standard of care therapy later this year to be followed by tumor-specific expansion cohorts. The study is designed to determine the MTD during a dose-escalation phase and to recommend a dose level for further study in the subsequent expansion phase. The expansion is designed to further evaluate the tolerability, biologic and anti-tumor effects of selected dose levels of CDX-527 in specific tumor types. Initial data from the Phase 1 study are anticipated in the first half of 2021.Recent Business Highlights On June 18, 2020, Celldex announced the closing of an underwritten public offering raising total gross proceeds of approximately 150.0 million.Second Quarter 2020 Financial Highlights and 2020 GuidanceCash Position: Cash, cash equivalents and marketable securities as of June 30, 2020 were 206.9 million compared to 53.7 million as of March 31, 2020. The increase was primarily driven by net proceeds of 141.4 million from our June 2020 underwritten public offering and net proceeds of 23.7 million from sales of common stock under our Controlled Equity OfferingSM agreement with Cantor completed in the second quarter prior to the offering in June. These increases were offset by second quarter cash used in operating activities of 11.2 million.Revenues: Total revenue was 0.2 million in the second quarter of 2020 and 3.0 million for the six months ended June 30, 2020, compared to 0.7 million and 2.1 million for the comparable periods in 2019. The increase in revenue for the six months ended June 30, 2020 compared to the six months ended June 30, 2019 was primarily due to the 1.8 million milestone payment from Rockefeller University related to our manufacturing and development services agreement, partially offset by a decrease in services performed under our manufacturing and research and development agreement with Duke University.RD Expenses: Research and development RD expenses were 9.7 million in the second quarter of 2020 and 21.4 million for the six months ended June 30, 2020, compared to 10.1 million and 21.2 million for the comparable periods in 2019. The increase in RD expense for the six months ended June 30, 2020 compared to the six months ended June 30, 2019 was primarily due to an increase in clinical trial and contract manufacturing expenses, partially offset by lower stock-based compensation expense.GA Expenses: General and administrative GA expenses were 3.5 million in the second quarter of 2020 and 7.2 million for the six months ended June 30, 2020, compared to 3.9 million and 8.8 million for the comparable periods in 2019. The decrease in GA expenses was primarily due to lower stock-based compensation expense.Changes in Fair Value Remeasurement of Contingent Consideration: The gain on fair value remeasurement of contingent consideration was 5.1 million during the second quarter of 2020 and 4.9 million during the six months ended June 30, 2020, primarily due to updated assumptions for CDX-3379 related milestones due to the discontinuation of the CDX-3379 program and the passage of time.Intangible Asset Impairment: The Company recorded a non-cash impairment charge of 3.5 million during the second quarter of 2020 due to the discontinuation of the CDX-3379 program.Net Loss: Net loss was 11.0 million, or 0.50 per share, for the second quarter of 2020, and 23.7 million, or 1.20 per share, for the six months ended June 30, 2020, compared to a net loss of 11.8 million, or 0.84 per share, for the second quarter of 2019 and 29.0 million, or 2.21 per share, for the six months ended June 30, 2019.Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at June 30, 2020 are sufficient to meet estimated working capital requirements and fund planned operations through 2023.Webcast and Conference Call Celldex executives will host a conference call at 4:30 p.m. ET today to discuss financial and business results and to provide an update on key 2020 objectives. 